Cycle view
- Bloc
- Organisation
- Théorie
- Pratique
- Autres
- Crédits
Information
Professor Ph HUBERT
Analytical chemistry
B36 - 4000 Liege
Phone number: 04/366 43 16
e-mail address: Ph.Hubert@uliege.be
Analytical chemistry
B36 - 4000 Liege
Phone number: 04/366 43 16
e-mail address: Ph.Hubert@uliege.be
Collegiality
For the ULiege: Vincent BIERLAIRE, Bruno BOULANGER, Raphaël DENOOZ, Laurence DENIS, Brigitte EVRARD, Marianne FILLET, Michel FREDERICH, Stéphanie GOFFLOT, Philippe HUBERT, Pierre LEBRUN, Roland MARINI, Dominique MARTIN, Bernard PIROTTE, Régis RADERMECKER, Jean-Michel VANDERHOFSTADT, Eric ZIEMONS.
For the ULB: Céline DEPORTE, Patrick DI STEFANO, François DUFRASNE, Walid EL AZAB, Véronique FONTAINE, Jonathan GOOLE, Anne LENAERS, Hugues MALONNE, Thierry SCHURMANS, Caroline STEVIGNY, Lorenzo TESOLIN, Pierre VAN ANTWERPEN, Francis VANDERBIST, Karen VAN MALDEREN, David VERMIJLEN, Zéna WIMANA.
For the UCLouvain: Catherine DRUEZ, Laure ELENS, Xavier MARCELIS, François-Xavier MATHY, Jacques POUPAERT, Thierry PRONCE, Joëlle LECLERCQ, Nevin SERBEST, Rita VANBEVER.
For the ULB: Céline DEPORTE, Patrick DI STEFANO, François DUFRASNE, Walid EL AZAB, Véronique FONTAINE, Jonathan GOOLE, Anne LENAERS, Hugues MALONNE, Thierry SCHURMANS, Caroline STEVIGNY, Lorenzo TESOLIN, Pierre VAN ANTWERPEN, Francis VANDERBIST, Karen VAN MALDEREN, David VERMIJLEN, Zéna WIMANA.
For the UCLouvain: Catherine DRUEZ, Laure ELENS, Xavier MARCELIS, François-Xavier MATHY, Jacques POUPAERT, Thierry PRONCE, Joëlle LECLERCQ, Nevin SERBEST, Rita VANBEVER.
| Code | Détails | Bloc | Organisation | Théorie | Pratique | Autres | Crédits |
|---|---|---|---|---|---|---|---|
| PHIN2034-1 | Biotechnologies | B1 | TA | 7 | |||
| Concepts and production of protein and oligonucleotide biopharmaceuticals
David Vermijlen
| 15 | - | - | ||||
| Living biopharmaceuticals, vaccines and biosecurity
Véronique Fontaine
| 6 | - | - | ||||
| Managing the risk of the release of cell and genetic products | 3 | - | - | ||||
| Formulation of biopharmaceuticals
Rita Vanbever
| 15 | - | - | ||||
| Quality control and analytical techniques in biopharmaceuticals, good practice and legal recommendations, part A | 5 | - | - | ||||
| Quality control and analytical techniques in biopharmaceuticals, good practice and legal recommendations, part B (post-translational modifications)
Cédric Delporte
| 3 | - | - | ||||
| From the laboratory to the pharmacy: legal requirements - part a: Patents and industrial protection
Patrick Di Stefano
| 5 | - | - | ||||
| From the laboratory to the pharmacy: legal requirements - part b: Statutes and regulatory constraints on biological products
Hugues Malonne
| 3 | - | - | ||||
| From the laboratory to the pharmacy: legal requirements - part c: Procedure for releasing batches and the legal framework of vaccines
Lorenzo Tesolin
| 1 | - | - | ||||
| From the laboratory to the pharmacy: legal requirements - part d: Organisation of quality assurance
Thierry Pronce
| 3 | - | - | ||||
| From the laboratory to the pharmacy: legal requirements - part e: Introduction to Biobanking | 3 | - | - | ||||
| PHIN2004-1 | Active substances | B1 | TA | 4 | |||
| Substances issues de recherches pharmacochimiques, part a | 10 | - | - | ||||
| Substances issues de recherches pharmacochimiques, part b
François Dufrasne
| 5 | - | - | ||||
| Substances d'origine naturelle, part a
Joëlle Leclercq
| 5 | - | - | ||||
| Substances d'origine naturelle, part b
Caroline Stevigny
| 5 | - | - | ||||
| Produits radiopharmaceutiques
Zena Wimana
| 10 | - | - | ||||
| PHIN2008-2 | Clinical viewpoints | B1 | TA | 5 | |||
| Métabolisme des médicaments et paramètres pharmacocinétiques
François-Xavier Mathy
| 20 | - | - | ||||
| Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) | 15 | - | - | ||||
| Information et pharmacovigilance | 10 | - | - | ||||
| PHIN2013-2 | Quality assurance and pharmaceutical management | B1 | TA | 7 | |||
| Principles of pharmaceutical management | 10 | - | - | ||||
| Quality assurance, part a : basic concepts and quality assurance organisation
Thierry Pronce
| 14,5 | - | - | ||||
| Quality assurance, part b: analytical technology of procedures and risk analysis
Xavier Marcelis
| 10 | - | - | ||||
| English applied to the pharmaceutical industry
Jacques Poupaert, Nevin Serbest
| 20 | - | - | ||||
| Pharmaceutical marketing | 7,5 | - | - | ||||
| PHIN2033-1 | Pharmaceutical technology | B1 | TA | 5 | |||
| Industrial pharmaceutical microbiology
Véronique Fontaine
| 9 | - | - | ||||
| Preformulation and selection of galenical forms
Jonathan Goole
| 15 | - | - | ||||
| Industrial production of galenical forms | 15 | - | - | ||||
| Industrial aspects of technological development including packaging | 10 | - | - | ||||
| PHIN2023-1 | Drug analysis | B1 | TA | 6 | |||
| Analytical control practices and pharmaceutical and biopharmaceutical control - part a
Pierre Van Antwerpen
| 7 | - | - | ||||
| Analytical control practices and pharmaceutical and biopharmaceutical control - part b | 5 | - | - | ||||
| Pharmaceutical and biopharmaceutical analytical methods - Approving and certifying equipment | 12 | - | - | ||||
| Pharmaceutical and biopharmaceutical analytical methods - Process Analytical Technology | 5 | - | - | ||||
| Statistical methods applied to the pharmaceutical industry
Laure Elens
| 15 | - | - | ||||
| Experimental planning and quality by design | 10 | - | - | ||||
| PHIN2029-2 | Regulation and the medical-social environment | B1 | TA | 8 | |||
| Economic aspects of drug development | 10 | - | - | ||||
| Legislation and procedures applied to pharmaceutical industry
Catherine Druez
| 10 | 5 | - | ||||
| Patents and protection
Patrick Di Stefano
| 5 | - | - | ||||
| Macroeconomic environment and pharmaco-economics
Hugues Malonne
| 7 | - | - | ||||
| CTD File (Common Technical Document) | 15 | - | - | ||||
| Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files
Karen Van Malderen
| 7,5 | - | - | ||||
| Regulations of preclinical and clinical studies, part b : clinical studies
Anne Lenaers
| 5 | - | - | ||||
| Regulations of preclinical and clinical studies, part c : pediatric studies
Thierry Schurmans
| 2,5 | - | - | ||||
| Specific regulatory issues, part a : medicine and herbal dietary supplement | 5 | - | - | ||||
| Aspects réglementaires particuliers, partim b : Préformulation et documentation du développement galénique
Francis Vanderbist
| 5 | - | - | ||||
| PHIN2032-1 | Visits and seminars organised in the pharmaceutical industry - [75h Visit]
François Dufrasne, Marianne Fillet, Joëlle Leclercq, Rita Vanbever
| B1 | TA | - | - | [+] | 3 |
| MTFE2000-1 | End-of-course work carried out during an internship in the pharmaceutical industry or in a university research lab - [12w Stage de contact]
François Dufrasne, Philippe Hubert, Joëlle Leclercq
| B1 | TA | - | - | [+] | 15 |